Navigation Links
Cell Therapeutics Resubmits Pixantrone NDA to FDA for Consideration of Accelerated Approval
Date:10/24/2011

>This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that accelerated approval by the FDA of pixantrone may not occur, that CTI may not be able to address satisfactorily the two key matters raised by the OND or other matters raised by the DODP, the OND and/or the FDA, that CTI's interpretation of the guidance provided by the OND, the DODP and/or the FDA may be different than the intent of the OND, the DODP and/or the FDA, that the OND, the DODP and/or the FDA may change its guidance, that the PIX301 study may not be deemed successful, that upon a re-review and/or resubmission of the NDA the FDA may find pixantrone to not be safe and/or effective, that the PIX301 study may still be deemed to be a failed study, that the FDA may require an additional clinical trial of pixantrone, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effectiveness of pixantrone, that CTI may not be able to provide satisfactory information in response to the FDA's Complete Response Letter, that the FDA may not complete the review of the NDA within six months of resubmission, that CTI may not obtain an FDA action date by April 2012, that CTI may not receive its 180 day responses from the EMA in the fourth quarter of 2011, that CTI may not obtain approval of the NDA from the FDA in the first half of 2012, CTI's ability to
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
2. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
3. Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients
4. Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
5. Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
6. Echo Therapeutics Hires Product Development Management Executive
7. Prime Therapeutics Demonstrates Willingness to Show Actual Pharmacy Costs
8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
9. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
10. Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
11. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) ... America (London, UK - November 16-18, 2015)" conference to their offering. ... America including Columbia, Peru , ... , Uruguay , Paraguay , ... America , Chile This seminar ...
(Date:9/2/2015)... , Sept. 2, 2015  Research and ... of the "An Introduction to the Medical ... conference to their offering. ... European medical device legislation. It will explain the ... of Notified Bodies, how to choose one and ...
(Date:9/2/2015)... 2015 Demers Ambulances is proud to announce it ... dealer for the states of Mississippi , ... . "This will enable Demers to effectively ... , Executive Vice-President for Demers Ambulances. "Emergency Equipment Professionals has ... and Alabama , giving them a strategic ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
... VIENNA, Austria, October 12 ... enzymes for the,chemical industry, announced today that it ... position of Senior Vice President Marketing &,Sales. Dr. ... of EUCODIS,Bioscience, products. In 2009 the Company has ...
... Foundation (CNF) today announced the launch of a new educational ... www.infantilespasmsinfo.org , is an educational resource developed by ... Spasms Awareness Week. , Earlier this year, the ... place this week in conjunction with the Child Neurology Society ...
Cached Medicine Technology:EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales 2EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales 3Child Neurology Foundation Announces the Launch of Infantilespasmsinfo.org 2Child Neurology Foundation Announces the Launch of Infantilespasmsinfo.org 3
(Date:9/3/2015)... York, New York (PRWEB) , ... September 03, 2015 , ... ... of the Division of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical ... College. , Dr. Winchell is a nationally renowned expert in care for the critically ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Global Vision ... that it will be spotlighting its award-winning print and artwork inspection solutions, ScanProof ... September 16 and 17 at the Olympia London, booth #F33 , Be the first ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... its upcoming virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” ... Health, Express Scripts and Milliman, will discuss how plan sponsors are adopting bold, ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Hunters Creek ... Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited ... for friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... ... ... ProScrub is a set of automated tools that allow Final Cut Pro ... without the use of keyframes. Utilize ProScrub's powerful sliders to determine the number ... to energetic video productions. ProScrub is a Final Cut Pro X ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... foods have a reputation for being full of flavor. ... for generations are,being prepared now in ways that can ... with high-calorie ingredients that,are fried or full of salt ... foods high in fat and calories can place people,at ...
... In New National Guidelines, WASHINGTON, Sept. 5 ... are getting a back-to-school boost,from the new asthma care ... primary importance of patient education,programs -- not just treatment ... their quality of life., Millions of children with ...
... Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty ... U.S. Food and Drug,Administration (FDA) product approval at its ... plans to seek FDA approval to,manufacture additional solid dosage ... is expected to be producing over 1 billion tablets,and ...
... Alliance is,offering an innovative program to help military leaders ... service to our country. Responding to the,needs of National ... author and nationally certified counselor, Joanne Steen, a widow,of ... Through a first-of-its-kind partnership, TriWest and Steen will ...
... Stahl Cowen Crowley LLC, of Chicago,IL, counsel to the ... Dana Corporation, Inc. has entered into a settlement,agreement with ... Dana had sought Bankruptcy Court approval to terminate all ... of the settlement Stahl,Cowen Crowley negotiated on behalf of ...
... Pet Owners to ... Surprise Attack, SACRAMENTO, Calif., Sept. 4 Most Californians ... encounters between,homeowners and wandering wildlife have prompted the California Veterinary,Medical ... what to,do to prevent an attack and how to react ...
Cached Medicine News:Health News:Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe) 2Health News:Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe) 3Health News:School is Cool for Asthma Patients of All Ages 2Health News:Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility 2Health News:TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program 2Health News:Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee 2Health News:Wildlife Sightings on the Rise in California 2Health News:Wildlife Sightings on the Rise in California 3
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: